{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-001407","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.303989+00:00","generated_at":"2026-05-28T09:08:19.656891+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Oncology provides LYMPHIR launch update; commercialization planned for H1 2025","bullets":["LYMPHIR (immunotherapy for CTCL) approved Aug 2024; launch targeted for first half of 2025.","First-year launch supply produced under commercial supply agreements with CMOs.","J-code application submitted under HCPCS; NCCN guidelines inclusion secured.","Patient assistance program and specialized field sales team under development.","Exploring international licensing partnerships and expanded indications for LYMPHIR."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-001407","json":"https://secwatch.observer/filing/0001213900-25-001407.json","markdown":"https://secwatch.observer/filing/0001213900-25-001407.md","text":"https://secwatch.observer/filing/0001213900-25-001407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025001407/0001213900-25-001407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025001407/ea0226984-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T09:08:19.656891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}